How health care executives feel about advances in AI

While legitimate concerns remain, EY survey respondents increasingly recognize the positive impact of the technology.

In brief

• Nearly every respondent in the sector (94%) believes AI will enhance productivity and efficiency, better enabling them to focus on higher-value tasks.
• Yet 83% also express concern about AI being used to personalize medical plans or help with diagnoses. Even more see the need for human supervision.

From the front lines of providers to the back offices of payers, generative AI (GenAI) is poised to be a transformative force across the health care and life sciences sectors — streamlining administrative tasks and redefining patient experiences, if handled thoughtfully and responsibly. In a heavily regulated industry like ours, introducing artificial intelligence (AI) into the workplace can create pathways to better care as well as tensions with employees and risks that must be managed.

Consolidating the views of employees across ranks and sectors, the pioneering EY AI Anxiety in Business Survey broadly reveals how people think about AI and its impact on their jobs — and considerations about how companies should communicate their AI intentions for greater success. A deeper look at the responses of 66 health care and life sciences executives at the VP level or above specifically reveals that 85% think AI adoption is not happening quick enough in the workplace. Further, 89% are anxious about falling behind and losing out on promotions without AI technology and more than half (53%) report having incorporated AI into their daily work.

Here are two trends worth highlighting as hospitals, insurers, pharma players and others plot their AI journeys.

1. AI garners widespread trust — but not enough for patient care currently

Nearly every health care executive surveyed (96%) say they trust AI, with 94% seeing it as a positive force in their workplace and 91% believing it has a positive effect on society as a whole. This is a promising foundation among executives near the highest ranks for building a more efficient future for the sector. 

Notably, 95% of the executives have advocated for the use of AI in their organizations, and around 72% of their organizations are using GenAI currently. Furthermore, 94% of the health care respondents believe that AI will enhance productivity and efficiency and allow them to focus on higher-value tasks.

The next step for executives is crafting the right value-added roadmap for moving forward amid such a high level of engagement. But the data reveals negative aspects as well, highlighting the importance of crafting a culture of awareness to understand how GenAI works, how it abides by regulation and how to scale responsibly while adding value.

A significant 85% of health care executives express worry about AI in the workplace in general, with this fear increasing for 62% of executives compared with the previous year. And 83% are concerned about AI being involved in personalizing medical plans or aiding in medical diagnoses. An overwhelming 91% believe AI needs human supervision, highlighting the importance of a human element in AI applications.

Additionally, 88% are comfortable with the use of AI in the hiring process, and over 50% prefer for the technology to be leveraged in tasks such as creating meeting notes, answering basic customer questions, analyzing data and forecasting trends, versus having humans perform those tasks on their own. While this suggests that the sector may be ready to embrace AI for administrative tasks (such as appointment scheduling, back-office functions and perhaps even patient education), barriers remain when considering the technology for helping with tasks directly tied to patient outcomes.

This aligns with a recent EY report on building the GenAI foundation in health care, showing how back-office use cases — such as billing, claims, waste reduction, scheduling and compliance — provide an entry point for getting comfortable with the technology and instituting proper data governance protocols. GenAI also shows promise in health care supply chains and drug discovery, while the next generation of patient care will likely rely on leveraging the technology with real-time, accurate biometric data through wearables. This evolution of patient monitoring can help prevent health conditions from escalating to crisis levels and move toward better quality of care.